AngioDynamics to Host Cardiovascular Leaders at Scientific Forum

Company's pipeline advances with recent FDA milestones and active clinical studies

Published on Feb. 4, 2026

Got story updates? Submit your updates here. ›

AngioDynamics, a medical technology company, announced it will convene leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum. The forum will focus on physician-led collaboration, clinical evidence development, and the real-world application of emerging cardiovascular technologies. This comes as the company has received recent FDA approvals and has active clinical studies across its cardiovascular portfolio, including for the AlphaReturn Blood Management System, the AlphaVac F1885 System, and the AngioVac System.

Why it matters

The Cardiovascular Scientific Forum reflects AngioDynamics' commitment to rigorous, evidence-based collaboration as its cardiovascular programs continue to advance. The recent FDA approvals and ongoing clinical studies demonstrate the company's focus on generating high-quality clinical evidence in areas of significant unmet need and equipping physicians with data-driven, minimally invasive options that can meaningfully impact patient outcomes.

The details

The Cardiovascular Scientific Forum will include sessions on collaborative cardiovascular care, reimbursement and coding considerations, investigator-led research presentations, and hands-on workshops. The forum will bring together interventional cardiologists, surgeons, and clinical researchers to review emerging data, discuss study design and evidence priorities, and align on research pathways supporting the company's cardiovascular pipeline. AngioDynamics recently received FDA approval for its IDE application for the APEX-Return pivotal study, which will evaluate the AlphaReturn Blood Management System, as well as FDA 510(k) clearance for a modified AlphaVac F1885 System and IDE approval for the PAVE study evaluating the AngioVac System.

  • AngioDynamics received FDA approval in November 2025 for its IDE application for the APEX-Return pivotal study.
  • AngioDynamics received FDA 510(k) clearance in November 2025 for a modified AlphaVac F1885 System.
  • AngioDynamics received FDA IDE approval in November 2025 for the PAVE study evaluating the AngioVac System.
  • The Cardiovascular Scientific Forum will take place on February 6-8, 2026 in Fort Lauderdale, Florida.

The players

Laura Piccinini

Senior Vice President and General Manager, Cardiovascular & International at AngioDynamics.

Juan Carlos Serna

Senior Vice President of Scientific & Clinical Affairs at AngioDynamics.

Got photos? Submit your photos here. ›

What they’re saying

“Innovation accelerates when the clinical community comes together around shared scientific priorities.”

— Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International

“These studies reflect our commitment to generating high-quality clinical evidence in areas of significant unmet need. We are focused on equipping physicians with data-driven, minimally invasive options that can meaningfully impact patient outcomes.”

— Juan Carlos Serna, Senior Vice President of Scientific & Clinical Affairs

What’s next

The APEX-Return study is expected to enroll up to 40 patients across multiple clinical sites and evaluate key safety and effectiveness endpoints, including device-related adverse events and procedural outcomes. The PAVE study is designed to generate clinical evidence supporting a minimally invasive approach for right-sided infective endocarditis and is expected to enroll up to 30 patients across multiple clinical sites.

The takeaway

AngioDynamics' Cardiovascular Scientific Forum and its recent regulatory milestones and active clinical studies demonstrate the company's commitment to rigorous, evidence-based collaboration and generating high-quality clinical data to support minimally invasive treatment options that can improve patient outcomes in areas of significant unmet need.